Specifically, no significant differentiation in the levels of Gal-3 was noted in a total of 580 breast cancer survivors treated with anthracycline-based chemotherapy with a mean (SD) of 15.8 ng/L (7.5) compared to the control group of total 580 patients, who have not received anthracycline-driven therapy with a mean (SD) of 16.1 ng/L (7.8) [136]. Here, LGALS3 is linked to breast carcinoma.